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Summary Operative treatment of asymptomatic carotid stenosis is well established since
results of Asymptomatic Carotid Atherosclerosis Study (ACAS) trial and Asymptomatic CarotidCarotid stenosis;
Medical treatment;
Primary prevention
Surgery Trial (ACST) were published. However, advances in medical treatment and recent trials
that revealed success of ‘‘best medical treatment’’ over interventional treatment for stenosis
of brain supplying arteries have raised the question, if ‘‘best medical treatment’’ should be
considered as ﬁrst option in case of asymptomatic carotid stenosis.
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perative treatment of asymptomatic carotid
tenosis
rterioarterial embolism is one of the most common stroke
tiologies. Although screening for carotid artery disease in
atients with lack of symptoms of cerebrovascular disease
n a routine base is not recommended, these patients are
dentiﬁed in many ways, particularly by a general physi-
ian, who examines the origin of a carotid bruit or by an
ngiologist screening for additional manifestations of arte-
iosclerosis in patients with peripheral arterial occlusive
isease. When asymptomatic carotid stenosis is diagnosed,
perative treatment of carotid stenosis is well established
ince results of the Asymptomatic Carotid Atherosclerosis
tudy (ACAS) trial [1] and the Asymptomatic Carotid Surgery
Operial (ACST) [2] were published.
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symptomatic carotid stenosis
owever, due to low absolute risk reduction of 1.2% the
fﬁcacy of surgical intervention has been questioned by
eans of calculations leading to a disclosure of costs of up
o 580.000 AUS$ for one stroke prevented with prophylac-
ic TEA in case of asymptomatic stenosis [3]. Costs may be
ven higher, taking into account, that the periprocedural
omplication rate of less than 3% in the multicenters trials
as not conﬁrmed in postapproval registries [4,5]. A recent
eta analysis went even further and calculated the differ-
nce in estimated fatal and disabling stroke-free survival
n case of endarterectomy in patients with asymptomatic
evere carotid stenosis as less than 4 days over the course
f 5 years [6].
eneﬁts of best medical treatment in
symptomatic carotid stenosis
ss under CC BY-NC-ND license.ate for ipsilateral stroke in untreated carotid stenosis has
een declined from 3.3% [7] in 1985 to 0.6% [8] in 2007. A
ecent meta analysis concluded, that this observation was
ot due to reduced incidence of risk factors but rather due
117
Table 1 Aggressive medical treatment (according to the
SAMMPRIS trial) [12].
Aspirin, at a dose of 325mg/day
Management of
Elevated systolic blood pressure
Aim: systolic blood pressure of less than 140mmHg
(<130mmHg in patients with diabetes)
Elevated low-density lipoprotein [LDL] cholesterol levels
Aim: LDL cholesterol level of less than 70mg/dl
(1.81mmol/l)
Diabetes
Elevated non-high-density lipoprotein [non-HDL]
cholesterol levels
Reduce/quit
Smoking
Excess weight
Insufﬁcient exercise (with the help of a lifestyle
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RMedical management of asymptomatic carotid stenosis
to improved medical treatment (particularly hypertensive
drugs and statines) [9].
At least for high-risk asymptomatic patients with poor
5-year survival (e.g., those with previous vascular surgery,
claudication, cardiac disease, an abnormal electrocardio-
gram, diabetes mellitus, or older age) medical treatment
was recommended since many years [10]. Recent guidelines
state that selection of asymptomatic patients for carotid
revascularization should be guided by an assessment of
comorbid conditions, life expectancy, and other individual
factors and should include a thorough discussion of the risks
and beneﬁts of the procedure with an understanding of
patient preferences brott [11].
Further evidence for efﬁcacy of best medical treatment
was gained by evaluation of the SAMMPRIS trial [12]. In this
trial (although focused on intracranial instead of extracra-
nial stenosis) a strict medical management according to a
previous published regimen [13,14] was able to mask any
probable effect of additional interventional treatment of
stenosis of intracranial arteries.
Speciﬁcation of best medical treatment in
asymptomatic carotid stenosis
Best medical treatment may be speciﬁed [15] as weight
and girth loss by means of dietary counseling, lipid-lowering
therapy (aimed at low-density lipoprotein level <2.6mmol/l
and a triglyceride <1.7mmol/l and high-density lipoprotein
level >1.0mmol/l), smoking cessation (if applicable), blood
pressure below 140/90mmHg (in case of diabetes or kidney
disease, below 130/80mmHg) by means of antihypertensive
agents and screening for diabetes and treatment (if appli-
cable) with a target glycated hemoglobin level of less than
7% and a moderate-intensity aerobic physical exercise pro-
gram (≥30min most days of the week) however, treadmill
testing should be performed in case of suspected coronary
heart disease, that is present with high incidence in patients
with carotid artery disease [16].
‘‘Pleiotropic’’ effects of best medical
treatment in asymptomatic carotid stenosis
Best medical treatment in patients is able to reduce also
incidence of stroke due to other causes beside steno-
sis of carotid artery as proven by the aggressive medical
treatment at the SPARCL study [17] that had reduced the
chance of a fatal stroke from 1.7% (placebo) to 1% (80mg
atorvastatin) at 5 years independent from type of stroke.
Remarkably there was an additional reduction of absolute
risk for cardiovascular events including myocardial infarc-
tion from 29% (placebo) to 22.4% (80mg atorvastatin) at
5 years. Therefore when interventional or operative treat-
ment of asymptomatic stenosis of carotid artery is preferred
over best medical treatment, more patients will die from
ischemic heart disease, which is only preventable with med-
ical therapy and not from either procedure in this particular
risk group (Table 1).modiﬁcation program)
note of caution
owever, an elevated risk for stroke compared to the
eneral population remains in patients with asymptomatic
arotid stenosis. Therefore education of this particular risk
roup about the symptoms of transient ischemic attack and
troke is necessary. In contrast to limited effect of large mass
edia public awareness campaigns about stroke symptoms
18], the effect may be even improved by direct contact
ith the physician and knowledge of the particular ﬁnding
f an asymptomatic carotid stenosis and the positive effect
f best medical treatment.
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